spacer
home > ebr > winter 2019 > challenges for small businesses in the global pharma market
PUBLICATIONS
European Biopharmaceutical Review

Challenges for Small Businesses in the Global Pharma Market

The pharmaceutical industry was considered a relatively ‘safe’ environment in which to be employed in the early 1990s. It was seen by many to be a recession-proof business where intellectual property (IP) and patents in particular were critical to profitability.

The business was global and powered by huge researchbased companies: Big Pharma, who took drugs all the way from preclinical research, through clinical development, to commercialisation. Companies like Glaxo, Merck, Pfizer, Eli Lilly, Bayer, and, in Sweden, the likes of Astra and Pharmacia, were multinational R&D-based powerhouses that dominated the life sciences landscape. In 1995, Astra had the biggest selling drug in the world: the proton pump inhibitor Losec® (omeprazole) and employed thousands of people in R&D. To its employees (which included the author at the time), the company seemed invincible.

The Changing Landscape

Drugs commanded high prices in the developed world, which represented almost the entire market in terms of value, with the US market being by far the most lucrative. Although the Hatch- Waxman Act – a US federal law designed to encourage generic drug manufacture and sale with a view to lowering prices – had been around for just a few years, generics companies were still somewhat smaller and often local organisations that tended not to enter the market until at least the basic patent covering a drug expired.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephen McNeeney PhD is an experienced UK and European Patent Attorney at Potter Clarkson, where he is a partner and Head of Chemistry and Pharma. Stephen completed his degree in chemistry and obtained a master’s degree in organic chemistry, before further achieving a PhD in the subject. He joined Potter Clarkson in 1996, specialising in pharmaceutical industry-related inventions. Today, Stephen acts for a variety of clients, ranging from Big Pharma, through SME drug discovery and drug development companies, to start-ups and university spin-outs, many of which are based outside the UK, particularly in Scandinavia.
spacer
Stephen McNeeny PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement